

On the use of corticosteroids for 2019-nCoV pneumonia

Lancet, The

395, 683-684

DOI: [10.1016/s0140-6736\(20\)30361-5](https://doi.org/10.1016/s0140-6736(20)30361-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The deacetylase sirtuin 6 protects against kidney fibrosis by epigenetically blocking β -catenin target gene expression. <i>Kidney International</i> , 2020, 97, 106-118.	2.6	53
2	Metastatic pulmonary dissemination as differential diagnosis of COVID-19 disease. <i>BMJ Case Reports</i> , 2020, 13, e237453.	0.2	3
3	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <i>Frontiers in Medicine</i> , 2020, 7, 546.	1.2	5
4	Gut Microbiota Dysbiosis as "Immune Hyperresponse" Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. <i>Microorganisms</i> , 2020, 8, 1514.	1.6	52
5	Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. <i>European Journal of Pharmacology</i> , 2020, 889, 173556.	1.7	30
6	Immunotherapeutic approaches to curtail COVID-19. <i>International Immunopharmacology</i> , 2020, 88, 106924.	1.7	57
7	Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis. <i>Shock</i> , 2020, 54, 638-643.	1.0	57
8	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 282, 103529.	0.7	43
9	Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 707.	1.3	5
10	Dexamethasone in severe COVID-19 infection: A case series. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101205.	0.2	7
11	Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 540187.	1.6	3
12	Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. <i>Asian Journal of Psychiatry</i> , 2020, 54, 102350.	0.9	67
14	Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection. <i>Anales De Pediatria (English Edition)</i> , 2020, 93, 323-333.	0.1	7
15	Repurposing existing drugs for COVID-19: an endocrinology perspective. <i>BMC Endocrine Disorders</i> , 2020, 20, 149.	0.9	36
16	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. <i>Frontiers in Endocrinology</i> , 2020, 11, 582870.	1.5	43
17	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
18	A case of corticosteroid-responsive SARS-CoV-2 related massive rhabdomyolysis. <i>IDCases</i> , 2020, 22, e00946.	0.4	4
19	Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report. <i>Journal De Mycologie Medicale</i> , 2020, 30, 101039.	0.7	20

#	ARTICLE	IF	CITATIONS
20	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1267-1292.	4.9	208
21	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 2304-2318.	1.8	42
22	Pros and cons of corticosteroid therapy for COVID-19 patients. <i>Respiratory Physiology and Neurobiology</i> , 2020, 280, 103492.	0.7	80
23	Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e195-e198.	1.1	74
24	Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 77-80.	0.2	9
25	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. <i>Intensive Care Medicine</i> , 2020, 46, 2265-2283.	3.9	52
26	Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 276.	7.1	4
27	Asthma and COVID-19: What do we know now. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842096624.	0.5	22
28	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. <i>Critical Care</i> , 2020, 24, 643.	2.5	42
29	<p>Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3907-3918.	1.1	2
30	COVID-19 Extrapulmonary illness - The Impact of COVID-19 on Nephrology care. <i>Disease-a-Month</i> , 2020, 66, 101057.	0.4	4
31	Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians. <i>Respiration</i> , 2020, 99, 667-677.	1.2	10
32	Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?. <i>Kidney International Reports</i> , 2020, 5, 1375.	0.4	1
33	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	0.9	12
34	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. <i>Antioxidants</i> , 2020, 9, 636.	2.2	39
35	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei. <i>Annals of Palliative Medicine</i> , 2020, 9, 2118-2130.	0.5	12
36	Hyperglycemia is a strong predictor of poor prognosis in COVID-19. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108338.	1.1	64
37	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82

#	ARTICLE	IF	CITATIONS
38	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1983-1994.	2.0	54
39	Review of guidelines and recommendations from 17 countries highlights the challenges that clinicians face caring for neonates born to mothers with COVID-19. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2192-2207.	0.7	57
40	Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 751-770.	1.3	10
41	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S798-S806.	0.6	83
42	Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2392.	1.0	34
43	SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. , 2020, 8, e000862.		33
44	The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 85-88.	0.3	5
45	The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. <i>Journal of Infection and Public Health</i> , 2020, 13, 1601-1610.	1.9	127
46	Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. <i>Medicine (United States)</i> , 2020, 99, e21429.	0.4	261
47	Adrenal Vascular Changes in COVID-19 Autopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1159-1160.	1.2	42
48	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. <i>Biochemical Pharmacology</i> , 2020, 180, 114184.	2.0	50
49	Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110529.	2.5	20
50	Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. <i>Scientific Reports</i> , 2020, 10, 13689.	1.6	29
51	Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. <i>Emerging Microbes and Infections</i> , 2020, 9, 1869-1877.	3.0	23
52	Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2637-2646.	0.3	149
53	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. <i>Cellular Immunology</i> , 2020, 358, 104240.	1.4	6
54	Manufacturing and Management of CAR T-Cell Therapy in COVID-19's Time: Central Versus Point of Care Proposals. <i>Frontiers in Immunology</i> , 2020, 11, 573179.	2.2	12
55	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 379-389.	0.9	12

#	ARTICLE	IF	CITATIONS
56	Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. <i>Npj Regenerative Medicine</i> , 2020, 5, 17.	2.5	48
57	The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13412.	1.7	21
58	Therapeutic response to corticosteroids in a critically ill patient with COVID-19. <i>Medicine (United States)</i> , 2020, 99, 1000000.	0.4	9
59	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2986.	1.0	44
60	Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2762.	1.0	20
61	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. <i>Clinical and Molecular Allergy</i> , 2020, 18, 17.	0.8	27
62	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
63	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 716-737.	0.6	40
64	Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. <i>Trials</i> , 2020, 21, 717.	0.7	35
65	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , 2020, 171, 106114.	1.3	23
66	Pharmacological treatments of COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1446-1478.	1.5	35
67	4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5953.	1.8	18
68	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. <i>Scientific Reports</i> , 2020, 10, 21291.	1.6	32
69	Liver transplant immunosuppression during the COVID-19 pandemic. <i>Gastroenterology and Hepatology (English Edition)</i> , 2020, 43, 457-463.	0.0	3
70	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8155.	1.2	63
71	Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. <i>Frontiers in Immunology</i> , 2020, 11, 581076.	2.2	6
72	Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option. <i>Annals of Translational Medicine</i> , 2020, 8, 1247-1247.	0.7	2
73	Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. <i>Mycopathologia</i> , 2020, 185, 607-611.	1.3	124

#	ARTICLE	IF	CITATIONS
74	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. <i>Autoimmunity Reviews</i> , 2020, 19, 102567.	2.5	521
75	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. <i>Autoimmunity Reviews</i> , 2020, 19, 102569.	2.5	173
76	Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 119-127.e4.	1.5	553
77	Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. <i>Clinics in Dermatology</i> , 2020, 38, 775-780.	0.8	15
78	Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 2114-2120.	2.9	322
79	Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. <i>American Journal of Transplantation</i> , 2020, 20, 2916-2922.	2.6	41
80	Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008280.	1.3	198
81	The Plight of Patients with Lupus Nephritis during the Outbreak of COVID-19 in Wuhan, China. <i>Journal of Rheumatology</i> , 2020, 47, 1452.2-1452.	1.0	12
82	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	2.5	32
83	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. <i>Molecular Psychiatry</i> , 2020, 25, 1611-1617.	4.1	70
84	An Update on Current Therapeutic Drugs Treating COVID-19. <i>Current Pharmacology Reports</i> , 2020, 6, 56-70.	1.5	438
85	Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead. <i>ACS Sensors</i> , 2020, 5, 1506-1513.	4.0	60
86	Efficacy and safety of acupuncture therapy for COVID-19: Retracted. <i>Medicine (United States)</i> , 2020, 99, e20407.	0.4	4
87	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. <i>Gynecologic Oncology</i> , 2020, 158, 16-24.	0.6	40
88	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6
89	Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. <i>Cmaj</i> , 2020, 192, E756-E767.	0.9	166
90	Coronavirus Disease 2019 (COVID-19) in Neonates and Children From China: A Review. <i>Frontiers in Pediatrics</i> , 2020, 8, 287.	0.9	37
91	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387

#	ARTICLE	IF	CITATIONS
92	Coronavirus disease 2019 in renal transplant recipients: Report of two cases. <i>Transplant Infectious Disease</i> , 2020, 22, e13329.	0.7	15
93	Caution against corticosteroid-based COVID-19 treatment. <i>Lancet, The</i> , 2020, 395, 1759-1760.	6.3	64
94	Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. <i>BMJ, The</i> , 2020, 369, m1936.	3.0	132
95	Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: a decision analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, , 1-9.	0.7	8
96	Epidemiological and clinical characteristics of discharged patients infected with SARS-CoV-2 on the Qinghai Plateau. <i>Journal of Medical Virology</i> , 2020, 92, 2528-2535.	2.5	21
97	Treatment algorithm for COVID-19: a multidisciplinary point of view. <i>Clinical Rheumatology</i> , 2020, 39, 2077-2084.	1.0	38
98	Successful use of methylprednisolone for treating severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 325-327.	1.5	61
99	COVID19: A Systematic Approach to Early Identification and Healthcare Worker Protection. <i>Frontiers in Public Health</i> , 2020, 8, 205.	1.3	28
100	Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 796-803.	1.5	9
101	Treating asthma in the COVID-19 pandemic. <i>Thorax</i> , 2020, 75, 822-823.	2.7	11
102	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	2.7	95
103	Utility and risk of dermatologic medications during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13833.	0.8	6
104	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 616.	1.8	56
105	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. <i>Biochemical Pharmacology</i> , 2020, 178, 114114.	2.0	89
106	The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19. <i>Complementary Therapies in Medicine</i> , 2020, 52, 102473.	1.3	18
107	Current and future therapeutical approaches for COVID-19. <i>Drug Discovery Today</i> , 2020, 25, 1545-1552.	3.2	15
108	A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	102
109	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e474-e484.	2.2	772

#	ARTICLE	IF	CITATIONS
110	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 23-25.	0.1	3
111	Inmunosupresión en el trasplante hepático en la era covid-19. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 457-463.	0.2	17
112	Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 627-627.	0.7	53
113	Regarding COVID-19 and the Otolaryngologist: Preliminary Evidence-Based Review. <i>Laryngoscope</i> , 2020, 130, E525.	1.1	0
115	A case series of COVID-19 patients with chronic hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2020, 92, 2785-2791.	2.5	29
116	COVID-19: Drug Targets and Potential Treatments. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12359-12386.	2.9	348
117	COVID-19 infection during the third trimester of pregnancy: Current clinical dilemmas. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 251, 268-271.	0.5	14
118	Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 476.	1.8	27
119	Bioactive natural compounds against human coronaviruses: a review and perspective. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1163-1174.	5.7	135
120	How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 899-904.	0.4	96
121	Can steroids reverse the severe COVID-19 induced cytokine storm?. <i>Journal of Medical Virology</i> , 2020, 92, 2866-2869.	2.5	66
122	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. <i>Clinical Lung Cancer</i> , 2020, 21, e547-e550.	1.1	13
123	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 507-516.	0.9	12
124	A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage. <i>Journal of Infectious Diseases</i> , 2020, 221, 1775-1781.	1.9	189
125	National Institute for the Infectious Diseases & L. Spallanzani-IRCCS. Recommendations for COVID-19 Clinical Management. <i>Gastroenterology Insights</i> , 2020, 12, 8543.	0.7	139
126	Clinical features and treatment of COVID-19 patients in northeast Chongqing. <i>Journal of Medical Virology</i> , 2020, 92, 797-806.	2.5	785
127	Kidney disease is associated with in-hospital death of patients with COVID-19. <i>Kidney International</i> , 2020, 97, 829-838.	2.6	2,075
128	COVID-19: what has been learned and to be learned about the novel coronavirus disease. <i>International Journal of Biological Sciences</i> , 2020, 16, 1753-1766.	2.6	579

#	ARTICLE	IF	CITATIONS
129	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.4	255
130	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1330-1333.	0.6	69
131	Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. <i>International Journal of Biological Sciences</i> , 2020, 16, 1698-1707.	2.6	284
132	Antipsoriatic treatments during COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020, 33, e13345.	0.8	16
133	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	2.7	114
134	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9490-9496.	3.3	1,601
135	Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 167-169.	0.6	38
136	Narrative review of the immune response against coronavirus: An overview, applicability for SARS-CoV-2, and therapeutic implications. <i>Anales De PediatrAa (English Edition)</i> , 2020, 93, 60.e1-60.e7.	0.1	3
137	Corticosteroid administration for viral pneumonia: COVID-19 and beyond. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1171-1177.	2.8	64
138	Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 73-76.	0.2	12
139	Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 971-978.	1.8	167
140	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. <i>Medicina (Lithuania)</i> , 2020, 56, 315.	0.8	4
141	The diagnostic value of detecting sudden smell loss among asymptomatic COVID-19 patients in early stage: The possible early sign of COVID-19. <i>Auris Nasus Larynx</i> , 2020, 47, 565-573.	0.5	24
142	Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome. <i>Genes and Diseases</i> , 2020, 7, 520-527.	1.5	51
143	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106080.	1.1	149
144	SARS-CoV2 and immunosuppression: A double-edged sword. <i>Transplant Infectious Disease</i> , 2020, 22, e13404.	0.7	34
145	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. <i>Frontiers in Public Health</i> , 2020, 8, 355.	1.3	34
146	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19. <i>Journal of Diabetes</i> , 2020, 12, 909-918.	0.8	27

#	ARTICLE	IF	CITATIONS
147	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	1.3	21
148	The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy. <i>Chinese Journal of Traumatology - English Edition</i> , 2020, 23, 190-195.	0.7	31
149	Tackling the cytokine storm in COVID-19, challenges and hopes. <i>Life Sciences</i> , 2020, 257, 118054.	2.0	64
150	SARS-COV-2 and eye immunity: the lesson was learned but we are not done yet. Brainstorming on possible pathophysiology inspired by ocular models. <i>International Ophthalmology</i> , 2020, 40, 1879-1883.	0.6	12
151	Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 98, 252-260.	1.5	71
152	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. <i>Drug Development Research</i> , 2020, 81, 919-941.	1.4	35
153	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. <i>International Journal of Biological Sciences</i> , 2020, 16, 2382-2391.	2.6	63
154	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Clinical Microbiology and Infection</i> , 2020, 26, 880-894.	2.8	36
155	COVID-19: treating and managing severe cases. <i>Cell Research</i> , 2020, 30, 370-371.	5.7	19
156	The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2020, 81, e13-e20.	1.7	270
157	Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report. <i>American Journal of Transplantation</i> , 2020, 20, 1922-1924.	2.6	55
158	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria. <i>Biomedica</i> , 2020, 40, 80-95.	0.3	4
160	Uso de antipalúdicos en el tratamiento del COVID-19: ¿una ventana de oportunidad?. <i>Medicina Clínica</i> , 2020, 155, 23-25.	0.3	5
161	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. <i>Frontiers in Medicine</i> , 2020, 7, 170.	1.2	141
162	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
163	Managing patients with cancer in the COVID-19 era. <i>European Journal of Cancer</i> , 2020, 132, 5-7.	1.3	16
164	COVID-19: Recommended sampling sites at different stages of the disease. <i>Journal of Medical Virology</i> , 2020, 92, 1383-1385.	2.5	16
165	COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights. <i>International Ophthalmology</i> , 2020, 40, 1057-1060.	0.6	32

#	ARTICLE	IF	CITATIONS
166	SARS-CoV-2 and viral sepsis: observations and hypotheses. <i>Lancet</i> , The, 2020, 395, 1517-1520.	6.3	936
167	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
168	Management and Treatment of COVID-19: The Chinese Experience. <i>Canadian Journal of Cardiology</i> , 2020, 36, 915-930.	0.8	147
169	Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. <i>European Urology</i> , 2020, 77, 748-754.	0.9	170
170	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103
171	Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. <i>Journal of Infection</i> , 2020, 81, e95-e97.	1.7	146
172	Current epidemiological and clinical features of COVID-19; a global perspective from China. <i>Journal of Infection</i> , 2020, 81, 1-9.	1.7	285
173	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. , 2020, 2, e0111.		87
174	Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. <i>British Journal of Haematology</i> , 2020, 189, 428-437.	1.2	282
175	Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. <i>Cancer Discovery</i> , 2020, 10, 775-778.	7.7	28
176	Methodological challenges of analysing COVID-19 data during the pandemic. <i>BMC Medical Research Methodology</i> , 2020, 20, 81.	1.4	64
177	The impact of the SARS-CoV-2 infection, with special reference to the hematological setting. <i>Journal of Medical Virology</i> , 2021, 93, 223-233.	2.5	23
178	Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 873-875.	1.8	28
179	The cytokine storm and COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 250-256.	2.5	1,007
180	COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13381.	0.7	26
181	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 24-36.	2.5	417
182	The Uncertain Role of Corticosteroids in the Treatment of COVID-19”Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 140.	2.6	1
183	COVID-19, liver transplant, and immunosuppression: Allies or foes?. <i>Transplant Infectious Disease</i> , 2021, 23, e13417.	0.7	9

#	ARTICLE	IF	CITATIONS
184	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
185	Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). <i>Medicina Intensiva</i> , 2021, 45, 104-121.	0.4	18
186	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 112-117.	2.8	33
187	Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. <i>Rheumatology</i> , 2021, 60, 399-407.	0.9	103
188	Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 94-98.	0.8	7
189	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	4.1	444
190	Pacientes críticos COVID-19 atendidos por anestesiólogos en el Noroeste de España: estudio multicéntrico, prospectivo, observacional. <i>Revista Española De Anestesiología Y Reanimación</i> , 2021, 68, 10-20.	0.1	15
191	SARS-CoV-2 associated COVID-19 in geriatric population: A brief narrative review. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 738-743.	1.8	8
192	Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 543-552.	1.0	14
194	Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study. <i>Journal of Internal Medicine</i> , 2021, 289, 906-920.	2.7	40
196	Immunopathogenesis and treatment of cytokine storm in COVID-19. <i>Theranostics</i> , 2021, 11, 316-329.	4.6	314
197	Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study. <i>Annals of Medicine</i> , 2021, 53, 181-188.	1.5	4
198	Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2828-2837.	2.5	21
199	Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era. <i>Thrombosis Research</i> , 2021, 198, 19-22.	0.8	17
200	Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. <i>Bioorganic Chemistry</i> , 2021, 106, 104490.	2.0	119
201	The Impact of COVID-19 Viral Infection on the Hypothalamic-Pituitary-Adrenal Axis. <i>Endocrine Practice</i> , 2021, 27, 83-89.	1.1	83
202	Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia. <i>Inflammation Research</i> , 2021, 70, 159-170.	1.6	17
203	COVID-19 and Solid Organ Transplantation: A Review Article. <i>Transplantation</i> , 2021, 105, 37-55.	0.5	241

#	ARTICLE	IF	CITATIONS
204	Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone. <i>IJU Case Reports</i> , 2021, 4, 22-24.	0.1	6
205	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <i>American Journal of Medicine</i> , 2021, 134, 166-175.	0.6	11
206	Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalised patients from Wuhan, China. <i>Clinical Respiratory Journal</i> , 2021, 15, 293-309.	0.6	17
207	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	1.9	232
208	Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements. <i>Journal of Medical Virology</i> , 2021, 93, 1817-1823.	2.5	19
209	T cell immunobiology and cytokine storm of COVID-19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
211	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. <i>Leukemia</i> , 2021, 35, 1121-1133.	3.3	61
212	Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. <i>European Radiology</i> , 2021, 31, 895-900.	2.3	48
213	Management of allergic patients during severe acute respiratory syndrome coronavirus-2 pandemic. <i>Allergy Asthma & Respiratory Disease</i> , 2021, 9, 115.	0.3	0
214	Shedding light on therapeutics in alopecia and their relevance to COVID-19. <i>Clinics in Dermatology</i> , 2021, 39, 76-83.	0.8	9
215	Clinical features and survival analysis of 97 coronavirus disease 2019 (COVID-19) patients. <i>Annals of Palliative Medicine</i> , 2021, 10, 7270-7279.	0.5	0
216	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
217	Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 748.	0.6	8
218	Outcome of early short-course corticosteroids in hospitalized patients with coronavirus disease-2019 (COVID-19): A report from a Saudi Arabian hospital. <i>Journal of Family and Community Medicine</i> , 2021, 28, 125.	0.5	2
219	Critically ill COVID-19 patients attended by anesthesiologists in northwestern Spain: A multicenter prospective observational study. <i>Revista Espa�ola De Anestesiolog�a Y Reanimaci�n (English Edition)</i> , 2021, 68, 10-20.	0.1	1
220	Managing active lupus nephritis during COVID-19 pandemic. <i>Indian Journal of Nephrology</i> , 2021, 31, 390.	0.2	0
221	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 231-247.	1.3	22
222	Outcomes and prognostic factors in 70 non-survivors and 595 survivors with COVID-19 in Wuhan, China. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 3611-3623.	1.3	9

#	ARTICLE	IF	CITATIONS
223	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <i>Journal of Medical Virology</i> , 2021, 93, 2694-2704.	2.5	27
224	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. <i>Respiration</i> , 2021, 100, 116-126.	1.2	99
225	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report. <i>Open Medicine (Poland)</i> , 2021, 16, 440-445.	0.6	2
226	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. <i>Clinical Rheumatology</i> , 2021, 40, 3227-3237.	1.0	29
227	Outbreak of Respiratory Infection: nCoV-2019 Current Status and Its Impact on Global Health. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 156-164.	0.1	1
230	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
231	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review. <i>Archives of Microbiology</i> , 2021, 203, 2043-2057.	1.0	9
232	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
233	Cross talk between COVID-19 and breast cancer. <i>Current Cancer Drug Targets</i> , 2021, 21, 575-600.	0.8	10
234	A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 673-680.	1.3	67
235	An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients. <i>Annals of Translational Medicine</i> , 2021, 9, 306-306.	0.7	8
236	Risk factors for mortality due to COVID-19 in intensive care units: a single-center study. <i>Annals of Translational Medicine</i> , 2021, 9, 276-276.	0.7	0
237	Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study. <i>Current Medical Science</i> , 2021, 41, 24-30.	0.7	9
238	The cytokine storm and thyroid hormone changes in COVID-19. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 891-904.	1.8	63
239	Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 919-923.	0.3	26
240	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 111-115.	0.1	3
241	Imaging features of COVID-19: What we can learn from SARS and MERS (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 356.	0.8	0
242	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. <i>Cell Metabolism</i> , 2021, 33, 258-269.e3.	7.2	87

#	ARTICLE	IF	CITATIONS
243	Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China. <i>Frontiers in Medicine</i> , 2021, 8, 582764.	1.2	4
244	Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 107.	7.1	10
245	Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors. <i>IScience</i> , 2021, 24, 102188.	1.9	13
246	Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. <i>European Journal of Pharmacology</i> , 2021, 894, 173854.	1.7	108
247	Cardiovascular Injury Due to SARS-CoV-2. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 167-177.	1.8	18
248	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 104-121.	0.1	11
249	Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 67.	1.1	39
250	Photodynamic Therapy: A Rational Approach Toward COVID-19 Management. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000.	0.2	4
251	COPD & COVID-19. <i>Archivos De Bronconeumologia</i> , 2021, 57, 162-164.	0.4	6
253	COPD & COVID-19. <i>Archivos De Bronconeumologia</i> , 2021, 57, 162-164.	0.4	11
254	Repositioned Drugs for COVID-19—the Impact on Multiple Organs. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1484-1501.	0.3	3
255	Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1293-1302.	1.0	12
256	Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 655666.	1.8	11
257	Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. <i>Autoimmunity Reviews</i> , 2021, 20, 102778.	2.5	47
258	Simulation Prediction and Control Strategy of COVID-19 Dynamic Contact Network in USA and Various States -- Based on Effective Regeneration Number and Improved Discrete SEIQDHR Model. <i>Journal of Physics: Conference Series</i> , 2021, 1865, 042071.	0.3	1
259	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1217-1225.	1.5	61
260	Rapid recovery achieved by intensive therapy after preterm cesarean section for worsening COVID-19-induced acute respiratory failure: A case report and literature review. <i>Case Reports in Women's Health</i> , 2021, 30, e00315.	0.2	1
261	The clinical course of critically ill COVID-19 patients receiving invasive mechanical ventilation with subsequent terminal weaning. <i>Medicine (United States)</i> , 2021, 100, e25619.	0.4	1

#	ARTICLE	IF	CITATIONS
262	Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Beforeâ€“After Study (CortiCOVID Study). <i>Open Respiratory Archives</i> , 2021, 3, 100086.	0.0	3
263	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of Tj ETQq1 1 0.784314 rgBT /Overlook). <i>Frontiers in Public Health</i> , 2021, 42, 5-18.	0.2	2
264	The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 615333.	1.2	22
265	Impact of corticosteroids in hospitalised COVID-19 patients. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000766.	1.2	27
266	Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study. <i>World Journal of Clinical Cases</i> , 2021, 9, 3546-3558.	0.3	4
267	Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2021, 2021, 1-12.	0.6	9
268	The Emergence of Novel Coronavirus Disease, Global Treatment Update and its Containment Strategies in Overpopulated Countries: A Review. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
269	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 636.	1.2	2
270	Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, 716-728.	0.6	39
271	Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosisâ€“Manifested Severe Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 670170.	1.6	8
272	Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study. <i>Cureus</i> , 2021, 13, e14933.	0.2	10
273	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
274	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <i>Nutrients</i> , 2021, 13, 1550.	1.7	26
275	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
276	Corticosteroid therapy for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25719.	0.4	37
277	Clinical Characteristics of Patients With Re-admitted of Novel Coronavirus 2019 (nCOVID-19) in Wenzhou, China. <i>Frontiers in Public Health</i> , 2021, 9, 649178.	1.3	2
278	Current Overviews on COVID-19 Management Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	9
279	Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. <i>BMJ, The</i> , 2021, 373, n1038.	3.0	50

#	ARTICLE	IF	CITATIONS
280	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 715-734.	1.3	4
281	Cytokine/Chemokine Expression Is Closely Associated Disease Severity of Human Adenovirus Infections in Immunocompetent Adults and Predicts Disease Progression. <i>Frontiers in Immunology</i> , 2021, 12, 691879.	2.2	6
282	Role of arachidonic cascade in COVID-19 infection: A review. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 154, 106539.	1.0	32
283	Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1553-1562.	2.0	12
284	A Gastroenterologist's™ clinical experience in COVID 19 and in-hospital mortality and length of stay analysis.. <i>Postgraduate Medicine</i> , 2021, 133, 592-598.	0.9	2
285	Predictors of mortality for hospitalized young adults aged less than 60 years old with severe COVID-19: a retrospective study. <i>Journal of Thoracic Disease</i> , 2021, 13, 3628-3642.	0.6	6
286	The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. <i>Computational Biology and Chemistry</i> , 2021, 92, 107482.	1.1	11
287	Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?. <i>Journal of Personalized Medicine</i> , 2021, 11, 556.	1.1	14
288	Identification and Prediction of Novel Clinical Phenotypes for Intensive Care Patients With SARS-CoV-2 Pneumonia: An Observational Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 681336.	1.2	2
289	Infecção por SARS-CoV-2 em pacientes transplantados de coração. Experiência em México. <i>Cirurgia Cardiovascular</i> , 2021, 29, 21-21.	0.1	0
290	The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19. <i>Chinese Medicine</i> , 2021, 16, 44.	1.6	16
291	Off Label Medication to Combat COVID-19: Review Results to Date. <i>Coronaviruses</i> , 2021, 2, 496-506.	0.2	1
292	Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19 – A theoretical perspective. <i>Medical Hypotheses</i> , 2021, 151, 110592.	0.8	8
293	Clinical features and predictors for patients with severe SARS-CoV-2 pneumonia at the start of the pandemic: a retrospective multicenter cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 666.	1.3	2
294	The role of immunomodulatory medications in the treatment of COVID-19. <i>Current Opinion in Rheumatology</i> , 2021, 33, 431-445.	2.0	4
295	A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review. <i>Coronaviruses</i> , 2021, 2, .	0.2	2
296	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 614-621.	0.1	3
297	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28

#	ARTICLE	IF	CITATIONS
298	Contemporary narrative review of treatment options for COVID-19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
299	Treating the endotheliopathy of SARS-CoV-2 infection with plasma: Lessons learned from optimized trauma resuscitation with blood products. <i>Transfusion</i> , 2021, 61, S336-S347.	0.8	2
300	Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1907-1931.	1.8	38
301	Corticosteroid use in respiratory viral infections – friend or foe?. <i>Current Opinion in Physiology</i> , 2021, 22, 100450.	0.9	2
302	Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19. <i>Current Molecular Pharmacology</i> , 2022, 15, 393-417.	0.7	6
303	Pathogenesis and treatment of cytokine storm in COVID-19. <i>Turkish Journal of Biology</i> , 2021, 45, 372-389.	2.1	18
304	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 28-45.	3.2	21
305	Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. <i>Journal of Infection and Public Health</i> , 2021, 14, 985-989.	1.9	25
306	Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 805.	1.3	4
307	Efficacy of Dexamethasone for the Treatment of COVID-19 Infection: A Perspective Review. <i>Current Drug Delivery</i> , 2021, 18, 546-554.	0.8	7
308	The Role of Steroids in the Management of COVID-19 Infection. <i>Cureus</i> , 2021, 13, e16841.	0.2	4
309	COVID-19 reinfection or reactivation in a renal transplant patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04672.	0.2	3
310	Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis. <i>Advances in Medical Sciences</i> , 2021, 66, 262-268.	0.9	3
311	Treatment Options for COVID-19-Related Guillain-Barré Syndrome. <i>Neurologist</i> , 2021, 26, 196-224.	0.4	7
312	Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy. <i>Emergency Care Journal</i> , 2021, 17, .	0.2	1
313	Immunotherapy Summary for Cytokine Storm in COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 731847.	1.6	9
314	Liver Injury in COVID-19: A Direct Hit or Collateral Damage?. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	2
315	SARS-CoV-2 and the Eye: The Pandora's Box of Ocular Immunology. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 502-509.	0.6	8

#	ARTICLE	IF	CITATIONS
316	Bronchial Asthma and COVID-19: Comorbidity Issues. Tuberculosis and Lung Diseases, 2021, 99, 6-14.	0.2	6
317	Antenatal corticosteroids in COVID-19 perspective. World Journal of Experimental Medicine, 2021, 11, 37-43.	0.9	1
318	The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research, 2021, 22, 245.	1.4	22
319	Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. Journal of Clinical Medicine, 2021, 10, 4019.	1.0	11
320	Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF- κ B signaling pathway. Phytomedicine, 2022, 95, 153784.	2.3	13
321	COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative review. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2021, 35, 351-368.	1.7	57
322	Molecular Docking Study of the Binding Interaction of Hydroxychloroquine, Dexamethasone and Other Anti-Inflammatory Drugs with SARS-CoV-2 Protease and SARS-CoV-2 Spikes Glycoprotein. Computational Molecular Bioscience, 2021, 11, 19-49.	0.6	2
323	COVID-19: Considerations for Children and Families During the Pandemic. Frontiers in Pediatrics, 2020, 8, 600721.	0.9	1
324	Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of Experimental Pharmacology, 2021, Volume 13, 1-13.	1.5	22
325	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
326	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Internal and Emergency Medicine, 2021, 16, 281-308.	1.0	46
327	COVID-19 Among Patients With Hepatitis B or Hepatitis C: A Systematic Review. Hepatitis Monthly, 2021, 20, .	0.1	2
328	Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman. Health Services Research and Managerial Epidemiology, 2021, 8, 233339282098663.	0.5	1
329	A comparison of radiographic features between non-survivors and survivors from ICU. European Journal of Radiology Open, 2021, 8, 100338.	0.7	2
330	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
331	Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. International Journal of Biological Sciences, 2021, 17, 1530-1537.	2.6	30
332	Management of Coronavirus Disease 2019 (COVID-19) Pandemic: From Diagnosis to Treatment Strategies. Advanced Therapeutics, 2021, 4, 2000173.	1.6	3
333	Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clinical Rheumatology, 2020, 39, 2031-2037.	1.0	9

#	ARTICLE	IF	CITATIONS
334	The epidemiology and clinical information about COVID-19. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1011-1019.	1.3	424
335	Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. <i>Journal of Infection and Public Health</i> , 2020, 13, 1652-1663.	1.9	47
336	Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 559-563.	1.6	8
337	Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort. <i>TH Open</i> , 2020, 04, e263-e270.	0.7	11
338	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
339	Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. <i>Clinical Infectious Diseases</i> , 2020, 71, 2167-2173.	2.9	95
340	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 360-368.	1.0	48
341	Implications of COVID-19 for the busy gastroenterologist. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 319-324.	0.8	5
342	Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 727-733.	0.9	114
343	Use of Corticosteroids in COVID-19. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 46-49.	0.5	1
359	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020, 27, e14-e25.	1.9	5
360	A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. <i>EXCLI Journal</i> , 2021, 20, 339-365.	0.5	17
361	Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China. <i>Aging</i> , 2020, 12, 12432-12440.	1.4	20
363	Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. <i>Current Drug Targets</i> , 2020, 21, 1703-1721.	1.0	9
364	Expression and Clinical Significance of SARS-CoV-2 Human Targets in Neoplastic and Non-Neoplastic Lung Tissues. <i>Current Cancer Drug Targets</i> , 2021, 21, 428-442.	0.8	8
365	Early Observation and Mitigation of Challenges in Diabetes Management of COVID-19 Patients in Critical Care Units. <i>Diabetes Care</i> , 2020, 43, e81-e82.	4.3	21
366	COVID-19: the endocrine opportunity in a pandemic. <i>Minerva Endocrinologica</i> , 2020, 45, 204-227.	1.7	31
367	COVID-19 and tuberculosis. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 59-65.	1.0	28

#	ARTICLE	IF	CITATIONS
368	The application of corticosteroids in COVID-19: A two-edged sword. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 66-70.	1.0	5
369	COVID-19: A 2020 update. <i>Indian Journal of Medical Sciences</i> , 0, 72, 88-94.	0.1	8
370	Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	48
371	Cytokine storm in COVID-19: Potential therapeutics for immunomodulation. <i>Journal of Research in Clinical Medicine</i> , 2020, 8, 38-38.	0.3	11
373	COVID-19 in China: From epidemiology to treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	4
374	Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 155.	0.8	6
375	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. <i>Infection and Chemotherapy</i> , 2020, 52, 317.	1.0	7
376	Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. <i>Multidisciplinary Respiratory Medicine</i> , 2020, 15, 713.	0.6	34
377	Management of Severe Asthma During the COVID-19 Pandemic in Korea. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 897.	1.1	2
378	THE EPIDEMIOLOGICAL AND CLINICAL FEATURES OF COVID-19 AND LESSONS FROM THIS GLOBAL INFECTIOUS PUBLIC. , 2020, 01, 01-24.		7
379	A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. <i>European Journal of Rheumatology</i> , 2020, 7, S102-S106.	1.3	1
380	Asthma and COVID-19: What do we know?. <i>Tuberkuloz Ve Toraks</i> , 2020, 68, 141-147.	0.2	9
381	Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. <i>Cureus</i> , 2020, 12, e8750.	0.2	13
382	Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study. <i>Clinical and Experimental Medicine</i> , 2022, 22, 487-497.	1.9	1
383	Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2301-2305.	1.0	8
385	Manejo de pacientes con enfermedad inflamatoria intestinal durante la pandemia de COVID-19. <i>Revista Colombiana De Gastroenterología</i> , 2020, 35, 37-44.	0.1	1
387	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. <i>BioScience Trends</i> , 2020, 14, 161-167.	1.1	8
388	Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11291.	1.2	18

#	ARTICLE	IF	CITATIONS
390	A REVIEW ON THE FIFTH PANDEMIC: CORONAVIRUS. Asian Journal of Pharmaceutical and Clinical Research, 0, , 25-31.	0.3	1
391	Therapy of patients with COVID-19: clinical studies and recommendations in different countries. Infusion & Chemotherapy, 2020, , 5-12.	0.0	2
392	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. Coronaviruses, 2020, 01, .	0.2	1
393	Clinical Characteristics and Treatment of COVID-19 Patients in the Affiliated Hospital of Qingdao University. Advances in Clinical Medicine, 2020, 10, 1246-1251.	0.0	0
394	Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. Beni-Suef University Journal of Basic and Applied Sciences, 2021, 10, 78.	0.8	22
395	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	1.7	20
396	COVID-19'İN DA SÄ°TOKÄ°N SALINIM SENDROMU VE TEDAVÄ° YAKLAÄžIMLARI. Turkish Journal of Pediatric Disease, 0, , 55-59.	0.0	0
397	COVID-19 Management: What We Need to Know?. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 441-445.	0.1	0
399	COVID-19 Treatment Experiences in the ICU. Osteopathic Family Physician, 2020, , 33-38.	0.2	0
400	Potential Drugs for Treating COVID-19 Infection. International Journal of Infection, 2020, 7, .	0.4	0
401	Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients. Cureus, 2020, 12, e10918.	0.2	18
402	Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. Kachestvennaya Klinicheskaya Praktika, 2020, , 23-27.	0.2	1
403	Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. Tanaffos, 2020, 19, 112-121.	0.5	0
404	Is there a place for anti-inflammatory therapy in COVID-19?. Journal of Thoracic Disease, 2020, 12, 7076-7080.	0.6	0
406	The Pathogenesis and Treatment of COVID-19: A System Review. Biomedical and Environmental Sciences, 2021, 34, 50-60.	0.2	4
407	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. Archives of Medical Science, 2021, 17, 546-550.	0.4	0
408	The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2. American Journal of Translational Research (discontinued), 2021, 13, 871-881.	0.0	1
409	Severe COVID-19-associated sepsis is different from classical sepsis induced by pulmonary infection with carbapenem-resistant klebsiella pneumonia (CrKP). Chinese Journal of Traumatology - English Edition, 2022, 25, 17-24.	0.7	7

#	ARTICLE	IF	CITATIONS
410	Blood Purification in Severe and Critical COVID-19 Patients: A Case Series of 5 Patients. <i>Frontiers in Public Health</i> , 2021, 9, 741125.	1.3	3
411	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	0.5	0
412	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. <i>Reviews in Medical Virology</i> , 2022, 32, e2314.	3.9	7
413	Steroid Treatment in Hematologic Patients with COVID-19: Experience of 2 cases. <i>Archives of Hematology Case Reports and Reviews</i> , 2020, , 028-033.	0.3	1
414	Efficacité et innocuité des corticostéroïdes dans le traitement de la COVID-19 selon des données pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitalière et le syndrome de détresse respiratoire aiguë : revue systématique et méta-analyse. <i>Cmaj</i> , 2020, 192, E1571-E1584.	0.9	1
415	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. <i>Archives of Medical Science</i> , 2020, 17, 546-550.	0.4	2
416	Is there a place for anti-inflammatory therapy in COVID-19?. <i>Journal of Thoracic Disease</i> , 2020, 12, 7076-7080.	0.6	0
417	Effectiveness of the Use of Dexamethasone in Treatment of Coronavirus Infections: A Systematic Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 518-521.	0.1	0
418	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 421.	1.0	8
419	Effect of a single high dose of vitamin D3 on cytokines, chemokines, and growth factor in patients with moderate to severe COVID-19. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 790-798.	2.2	23
420	PRCTC: a machine learning model for prediction of response to corticosteroid therapy in COVID-19 patients. <i>Aging</i> , 2022, 14, 54-72.	1.4	1
421	Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010176.	2.1	20
422	Repurposing of <i>Mycobacterium indicus pranii</i> for the severe form of COVID-19 patients in India: A cohort study. <i>Journal of Medical Virology</i> , 2021, , .	2.5	5
423	SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2102-2123.	1.1	3
424	COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842110732.	0.5	3
425	An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 412.	0.3	3
426	Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical care. <i>Infectious Diseases Now</i> , 2022, 52, 130-137.	0.7	6
428	Use of corticosteroid hormones in patients with moderate COVID-19: what goals can be achieved. <i>Epidemiology and Infectious Diseases (Russian Journal)</i> , 2021, 26, 23-36.	0.1	0

#	ARTICLE	IF	CITATIONS
429	Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19. <i>Obshchaya Reanimatologiya</i> , 2022, 18, 11-16.	0.2	2
430	Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 109-115.	0.1	1
431	Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study. <i>Value in Health</i> , 2022, , .	0.1	6
432	Pitfalls of Early Systemic Corticosteroids Home Therapy in Older Patients with COVID-19 Pneumonia. <i>Geriatrics (Switzerland)</i> , 2022, 7, 21.	0.6	4
433	Ofelein i mi Vlaptinâ€”Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
434	Co-Administration of Menstrual Blood-Derived Stem Cells and Remdesivir for the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Induced Pneumonia: A Research Protocol. , 2022, 6, 1-12.		1
435	Pharmacistsâ€™™ knowledge, attitude and practice in the UAE toward the public health crisis of COVID-19: A cross-sectional study. <i>Pharmacy Practice</i> , 2022, 20, 2628-2628.	0.8	7
436	Methodology and experiences of rapid advice guideline development for children with COVID-19: responding to the COVID-19 outbreak quickly and efficiently. <i>BMC Medical Research Methodology</i> , 2022, 22, 89.	1.4	1
437	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	3.1	23
438	The role and place of pathogenetic therapy with glucocorticosteroid hormones in the treatment of patients with novel coronavirus infection (COVID-19). <i>Terapevticheskie Arkhiv</i> , 2021, 93, 1395-1400.	0.2	1
439	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
440	é†ç—†COVIDâ€“19æ,£è€...ã«ãšã'ã,ã¼4µè¥²çš,,ãºã-¥ã'¼ãšç®¼ç†ãã®ã,1ãf†ãfã,ãf%ºã®æšã,žçµ,ãº†ã*28æ—¥æ»ãº:çž†ã®é—¢é€£ã®æœš Kyukyu Igakukai Zasshi, 2022, 33, 121-127.	0.0	0
441	Meta-analysis and systematic review: The administration of glucocorticoids, as a line of treatment for COVID-19 patients, could result in lowering mortality. , 2022, 9, .		1
444	Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. <i>Frontiers in Microbiology</i> , 2022, 13, 813358.	1.5	19
446	The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. <i>Covid</i> , 2022, 2, 540-552.	0.7	12
447	Treatment strategies of Covid-19. A rheumatology perspective.. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	3
448	COVID-19 and corticosteroids: a narrative review. <i>Inflammopharmacology</i> , 2022, 30, 1189-1205.	1.9	39
451	Low-to-Moderate Dosage and Short-Term Use of Corticosteroids Benefit Patients With Severe COVID-19 Infections. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1

#	ARTICLE	IF	CITATIONS
452	Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial. <i>International Journal of Infectious Diseases</i> , 2022, 122, 659-664.	1.5	9
453	Steroids Therapy in Patients With Severe COVID-19: Association With Decreasing of Pneumonia Fibrotic Tissue Volume. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
454	Effect of treatment regimens in severe COVID pneumonia at an Indian tertiary care hospital: An observational, real-world study. <i>Medical Journal Armed Forces India</i> , 2022, 78, 469-474.	0.3	0
455	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	2.0	10
456	Care of the Seriously Ill Patient with SARS CoV-2. <i>Medical Clinics of North America</i> , 2022, , .	1.1	1
457	The The use of corticosteroid therapy for COVID-19 patients: an evidence-based overview. <i>Revista Ciencias Em Saude</i> , 2022, 12, 4-11.	0.0	0
458	Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	1
459	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
460	Transmission, Medical Consequences, and Prevention/Treatment of COVID-19 Infection. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 45-67.	0.1	0
461	Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 48464-48475.	4.0	3
462	Global research trends of steroid-induced osteonecrosis of the femoral head: A 30-year bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
463	Highly pathogenic coronaviruses and the kidney. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113807.	2.5	1
464	COVID-19: From Pathophysiology to Treatment. , 0, , .		0
465	Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model. <i>European Journal of Pharmacology</i> , 2023, 938, 175392.	1.7	1
466	Potential influence of COVID-19 and dexamethasone on the reproductive system: what we know and can expect. <i>Human Fertility</i> , 2023, 26, 38-49.	0.7	0
468	Efficacy and safety profile of corticosteroids and non-steroidal anti-inflammatory drugs in COVID-19 management: A narrative review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
469	Modification of Sympathetic and Hypothalamic Responses to Prevent Complications of COVID-19: â€œDam and Wall Conceptâ€• Stresses, 2023, 3, 153-166.	1.8	0
470	Timing of corticosteroids in non-severe nonhospitalized COVID-19 patients: open-label, two-center, randomized controlled study (TICS-COV19 study). <i>Korean Journal of Internal Medicine</i> , 0, , .	0.7	1

#	ARTICLE	IF	CITATIONS
471	Analysis of implementation status and effectiveness of treatments in the Chinese diagnosis and treatment recommendation for COVID-19 at local hospitals. <i>Community Acquired Infection</i> , 0, 9, .	0.1	0
472	Corticosteroid Therapy in Severe Cases of Pneumonia Caused by SARS-CoV-2. <i>Cureus</i> , 2022, , .	0.2	0
473	Clinical characteristics and remission of nine cases with coronavirus disease 2019 infection in Zunyi, Southwest of China: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31494.	0.4	0
474	Clinical efficacy of low-dose glucocorticoid therapy for critically ill patients with severe fever with thrombocytopenia syndrome: A retrospective cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 130, 153-160.	1.5	0
475	Therapeutic Effects of Corticosteroids for Critical and Severe COVID-19 Patients. <i>Communications in Computer and Information Science</i> , 2022, , 260-287.	0.4	0
476	Therapeutic options in COVID-19. , 2023, , 647-672.		0
477	Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. <i>Journal of International Medical Research</i> , 2023, 51, 030006052211492.	0.4	0
478	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	0.6	1
486	Cancer management during the COVID-19 world pandemic. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
492	Chemical and physiological effects of dexamethasone drug to hyperglycemia with Covid-19 patients. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0